Literature DB >> 6196758

Prognosis of Fallot's tetralogy after palliative operations: 10-25 year follow-up.

P Presbitero, P D'Antonio, A Brusca, M Morea.   

Abstract

The condition of 350 patients with Fallot's tetralogy (FT) who had palliative surgery (aortopulmonary shunt or transventricular valvotomy) was reviewed 10-25 years later: 136 patients (38%) are alive without any further operation, 106 (30%) have recovered completely, and 108 (31%) have died. Actuarial survival at 25 years of the patients who had palliation was 50% compared to 83% for the group who subsequently had complete correction. After the first five years the mortality rates became 5% per year. Of the patients who were not reoperated upon, 33% felt that the quality of their life was normal, 40% were limited, and 27% were severely limited. The older the patient at palliative procedure, the better the clinical course and the longer the interval before another operation, if the latter was needed at all. Of the patients who had a Brock procedure, the survival rate at 25 years was 80% and the clinical condition was good in 72% of the patients who had not been reoperated upon. Comparison with the natural history of unoperated FT reported by others indicates that the palliative procedures prolonged life in our series; mortality continued at a steady rate for a few years after palliative surgery, probably as a function of the severity of the anatomical and functional abnormality, and independently of the age at which the palliative procedure was performed. Among the palliative procedures, the Brock operation was followed by the best results both in relieving symptoms and in prolonging life.

Entities:  

Mesh:

Year:  1983        PMID: 6196758     DOI: 10.1007/BF02242252

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  14 in total

1.  BLALOCK-TAUSSIG ANASTOMOSIS FOR TETRALOGY OF FALLOT. A TEN-TO-FIFTEEN YEAR FOLLOW-UP.

Authors:  A M HARRIS; N SEGEL; J M BISHOP
Journal:  Br Heart J       Date:  1964-03

2.  Ten to thirteen year follow-up on patients after a Blalock-Taussig operation.

Authors:  H B TAUSSIG; H CRAWFORD; S PELARGONIO; S ZACHARIOUDAKIS
Journal:  Circulation       Date:  1962-04       Impact factor: 29.690

3.  Long-term results of aortic-pulmonary anastomosis for tetralogy of Fallot. An analysis of the first 100 cases eleven to thirteen years after operation.

Authors:  M H PAUL; R A MILLER; W J POTTS
Journal:  Circulation       Date:  1961-04       Impact factor: 29.690

4.  The tetralogy of Fallot in older persons up to the fifth decade.

Authors:  S E LEEDS
Journal:  Am J Surg       Date:  1958-08       Impact factor: 2.565

5.  Five-year postoperative results of first 500 patients with Blalock-Taussig anastomosis for pulmonary stenosis or atresia.

Authors:  S R BAUERSFELD; D G MCNAMARA; H B TAUSSIG; B D WHITE
Journal:  Circulation       Date:  1956-10       Impact factor: 29.690

6.  Status of the adult and adolescent after repair of tetralogy of Fallot.

Authors:  A Garson; M R Nihill; D G McNamara; D A Cooley
Journal:  Circulation       Date:  1979-06       Impact factor: 29.690

7.  Long-term results of aortopulmonary anastomosis for tetralogy of fallot: morbidity and mortality, 1946-1969.

Authors:  R B Cole; A J Muster; D E Fixler; M H Paul
Journal:  Circulation       Date:  1971-02       Impact factor: 29.690

8.  Long-time observations on the Blalock-Taussig operation. I. Results of first operation.

Authors:  H B Taussig; A Crocetti; E Eshaghpour; R Keinonen; K N Yap; D Bachman; N Momberger; H Kirk
Journal:  Johns Hopkins Med J       Date:  1971-11

9.  Long-term evaluation (12 to 22 years) of open heart surgery for tetralogy of Fallot.

Authors:  V Fuster; D C McGoon; M A Kennedy; D G Ritter; J W Kirklin
Journal:  Am J Cardiol       Date:  1980-10       Impact factor: 2.778

10.  Life expectancy without surgery in tetralogy of Fallot.

Authors:  E G Bertranou; E H Blackstone; J B Hazelrig; M E Turner; J W Kirklin
Journal:  Am J Cardiol       Date:  1978-09       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.